TrialCancer medicine2017
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.
Feng-Cai Zhu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
28 papers cite it
this paperpooled ittrialcites it